The Definitive Industry Forum for CKD Drug Development

Advance More Personalized Therapies for Rare & Common Kidney Diseases

The 6th CKD Drug Development Summit is the definitive forum for KOLs, industry experts, and regulators to bring kidney innovation onto the next generation of drug development, uniting 200+ biopharma stakeholders, from scientific research to clinical development and outcomes, across three days of concentrated discussion.

From uncovering the genetic architecture of specific CKD subgroups and revolutionizing translatable models of renal pathophysiology, to breaking new ground in CKD trial design and implementing new therapies into the treatment paradigm, join Novo Nordisk, Boehringer Ingelheim, Eli Lilly, AstraZeneca, the FDA, Regeneron, Novartis and more to collaborate and drive progress of precision medicine and reinvent the landscape of rare and common kidney disease treatments.